Table 3. Outcomes of aspirin desensitization (n = 214).
| Aspirin desensitization response | Value | ||
|---|---|---|---|
| Patients who experienced reaction during desensitization (n = 57, 26.6%) | |||
| Type of reactions experienced | |||
| Angioedema | 44 (77.2) | ||
| Rash | 10 (17.5) | ||
| Respiratory symptoms | 5 (8.8) | ||
| Itch | 4 (7.0) | ||
| Rhinorrhea | 1 (1.8) | ||
| Neck tightness | 1 (1.8) | ||
| Others* | 4 (7.0) | ||
| Step at which reaction occurred | |||
| 9 | 1 (1.8) | ||
| 10 | 6 (10.5) | ||
| 11 | 50 (87.7) | ||
| Cumulative aspirin dose at which reaction occurred (mg) | 244.2 ± 38.2 | ||
| Patients who did not start aspirin therapy (n = 63, 29.4%) | |||
| Reasons for not commencing aspirin therapy | |||
| Reaction during or after procedure | 47 (74.6) | ||
| Not indicated | 18 (28.6) | ||
| Choice of SAPT with alternative agents for minor CAD | 3 (4.8) | ||
| Prioritization of other issues | 2 (3.2) | ||
| Patients who started aspirin therapy (n = 151, 70.6%) | |||
| Aspirin therapy discontinued subsequently | 30 (19.9) | ||
| Reason for discontinuation of aspirin therapy | |||
| No longer indicated | 11 (36.7) | ||
| Bleeding | 5 (16.7) | ||
| Adverse drug reactions | 5 (16.7) | ||
| Stopping for procedure | 3 (10.0) | ||
| Hypersensitivity reaction | 2 (6.7) | ||
| Others | 4 (13.3) | ||
Values are presented as number (%) or mean ± standard deviation.
SAPT, single antiplatelet therapy; CAD, coronary artery disease.
*Includes fever, numbness over jaw, nasal voice, and conjunctivitis.